ProQR Therapeutics
Begoña Carreño, PhD, joins the ProQR’s Supervisory Board in 2023. Dr. Carreño was most recently Global Business Development & Licensing Head (BD&L) in the Ophthalmology franchise at Novartis Pharma, AG, based in Basel, Switzerland. She has more than 20 years of pharmaceutical development and strategy leadership, having led BD&L efforts at Novartis across five different therapeutic franchises, as well as a proven track record in licensing deals and M&A. Before joining Novartis, she was the Head of External Pharmaceutical projects at Almirall (Barcelona, Spain). Dr. Carreño holds a PhD in Drug Delivery from the London School of Pharmacy (UK) and a BSc in Biochemistry from Keele University (UK).
This person is not in the org chart
This person is not in any offices
ProQR Therapeutics
1 followers
ProQR Therapeutics develops RNA therapies to potentially transform the lives of patients suffering from inherited retinal diseases.